Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
WALTHAM, Mass., Aug. 14, 2017 -- Interleukin Genetics, Inc. (OTCQB:ILIU) today announced it has filed a Form 15 with the Securities and Exchange Commission completing the process of delisting and deregistering its securities under the Exchange Act.
The Company announced on July 25, 2017, that it would begin the process of delisting and deregistering its securities and filed a Form 25 on August 4, 2017 as part of the process.
About Interleukin Genetics, Inc.
Interleukin Genetics, Inc. (OTCQB:ILIU) develops and markets proprietary genetic tests for chronic inflammatory diseases and health-related conditions, with significant expertise in metabolism and inflammation. Our tests provide information that is not otherwise available, to empower individuals and their healthcare providers to manage their health and wellness through genetics-based insights and actionable guidance, including pharmacogenomics information to guide development and use of therapeutics. Interleukin Genetics’ lead products include our proprietary cardiovascular test to guide treatment of high risk patients; our proprietary ILUSTRA Inflammation Management Program; and its Inherent Health® line of genetic tests. Interleukin Genetics is headquartered in suburban Boston and operates an on-site DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit www.ilgenetics.com.
Contact: Eric Collins 617-886-6045
